Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUT00201 in MEAK
NCT05873062Phase 1Completed
- Sponsor
- Autifony Therapeutics
- Start
- May 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AUT00201 in Progressive Myoclonus Epilepsy Type 7 (EPM7) (2 arms), sponsored by Autifony Therapeutics. Primary endpoint: Treatment-Related Adverse Events at 19 days. Started May 2023; status: completed.
02
Drugs
AUT00201
03
Conditions
Progressive Myoclonus Epilepsy Type 7 (EPM7)
Beyond the preview
Go deeper on NCT05873062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05873062.